Tirzepatide is more effective due to its dual GIP/GLP-1 receptor mechanism, but oral semaglutide eliminates the need for injections entirely
These stages, ranging from mild to severe, help physicians assess the condition and develop an appropriate treatment plan while assisting patients to understand how their condition may progress

During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

This article is for educational purposes only and does not replace the advice of a qualified healthcare or nutrition professional
These shots are like the fast track for glutathione to jump straight into your bloodstream